Overview of C3 Glomerulopathy

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2016 May 21

PMID 27200326

Citations 4

Authors

Vimal Master Sankar Raj

Roberto Gordillo

Deepa H Chand

Affiliations

Soon will be listed here.

Abstract

C3 glomerulopathy is an umbrella term, which includes several rare forms of glomerulonephritis (GN) with underlying defects in the alternate complement cascade. A common histological feature noted in all these GN is dominant C3 deposition in the glomerulus. In this review, we will provide an overview of the complement system as well as mediators, with an introduction to pharmaceutical agents that can alter the pathway.

Citing Articles

Diagnostic and Prognostic Comparison of Immune-Complex-Mediated Membranoproliferative Glomerulonephritis and C3 Glomerulopathy.

Kovala M, Seppala M, Raisanen-Sokolowski A, Meri S, Honkanen E, Kaartinen K Cells. 2023; 12(5).

PMID: 36899849 PMC: 10000503. DOI: 10.3390/cells12050712.

Endocarditis-Associated C3-Dominant Glomerulonephritis in a Patient With a Solitary Kidney.

Chowdhury L, Alobaidi A, Lytvak I Cureus. 2022; 14(8):e27675.

PMID: 35935112 PMC: 9351630. DOI: 10.7759/cureus.27675.

Infection Associated C3 Glomerulopathy Presenting as Severe Crescentic Glomerulonephritis.

De Silva L, Jayasinghe D, Amarathunga P Case Rep Nephrol. 2021; 2021:6295543.

PMID: 34616577 PMC: 8490074. DOI: 10.1155/2021/6295543.

Diverse Clinical Presentations of C3 Dominant Glomerulonephritis.

Hanna R, Hou J, Hasnain H, Arman F, Selamet U, Wilson J Front Med (Lausanne). 2020; 7:293.

PMID: 32695788 PMC: 7338606. DOI: 10.3389/fmed.2020.00293.

References

Rabasco C, Cavero T, Roman E, Rojas-Rivera J, Olea T, Espinosa M . Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int. 2015; 88(5):1153-60. DOI: 10.1038/ki.2015.227. View

McGinley E, Watkins R, McLay A, Boulton-Jones J . Plasma exchange in the treatment of mesangiocapillary glomerulonephritis. Nephron. 1985; 40(4):385-90. DOI: 10.1159/000183504. View

Jokiranta T, Solomon A, Pangburn M, Zipfel P, Meri S . Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol. 1999; 163(8):4590-6. View

Licht C, Heinen S, Jozsi M, Loschmann I, Saunders R, Perkins S . Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int. 2006; 70(1):42-50. DOI: 10.1038/sj.ki.5000269. View

Noris M, Remuzzi G . Atypical hemolytic-uremic syndrome. N Engl J Med. 2009; 361(17):1676-87. DOI: 10.1056/NEJMra0902814. View

Sim R, Day A, Moffatt B, Fontaine M . Complement factor I and cofactors in control of complement system convertase enzymes. Methods Enzymol. 1993; 223:13-35. DOI: 10.1016/0076-6879(93)23035-l. View

Bomback A, Smith R, Barile G, Zhang Y, Heher E, Herlitz L . Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol. 2012; 7(5):748-56. PMC: 3338285. DOI: 10.2215/CJN.12901211. View

Servais A, Fremeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B . Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet. 2006; 44(3):193-9. PMC: 2598029. DOI: 10.1136/jmg.2006.045328. View

Martinez-Barricarte R, Heurich M, Valdes-Canedo F, Vazquez-Martul E, Torreira E, Montes T . Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest. 2010; 120(10):3702-12. PMC: 2947238. DOI: 10.1172/JCI43343. View

10.

Habbig S, Mihatsch M, Heinen S, Beck B, Emmel M, Skerka C . C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int. 2008; 75(11):1230-1234. DOI: 10.1038/ki.2008.354. View

11.

Gale D, Goicoechea de Jorge E, Cook H, Martinez-Barricarte R, Hadjisavvas A, McLean A . Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet. 2010; 376(9743):794-801. PMC: 2935536. DOI: 10.1016/S0140-6736(10)60670-8. View

12.

Kurtz K, Schlueter A . Management of membranoproliferative glomerulonephritis type II with plasmapheresis. J Clin Apher. 2002; 17(3):135-7. DOI: 10.1002/jca.10026. View

13.

Moore I, Strain L, Pappworth I, Kavanagh D, Barlow P, Herbert A . Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2009; 115(2):379-87. PMC: 2829859. DOI: 10.1182/blood-2009-05-221549. View

14.

Schmidt C, Herbert A, Hocking H, Uhrin D, Barlow P . Translational mini-review series on complement factor H: structural and functional correlations for factor H. Clin Exp Immunol. 2007; 151(1):14-24. PMC: 2276926. DOI: 10.1111/j.1365-2249.2007.03553.x. View

15.

Herlitz L, Bomback A, Markowitz G, Stokes M, Smith R, Colvin R . Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol. 2012; 23(7):1229-37. PMC: 3380652. DOI: 10.1681/ASN.2011121186. View

16.

Oberkircher O, Enama M, West J, Campbell P, Moran J . Regression of recurrent membranoproliferative glomerulonephritis type II in a transplanted kidney after plasmapheresis therapy. Transplant Proc. 1988; 20(1 Suppl 1):418-23. View

17.

Turnberg D, Botto M . The regulation of the complement system: insights from genetically-engineered mice. Mol Immunol. 2003; 40(2-4):145-53. DOI: 10.1016/s0161-5890(03)00110-x. View

18.

Smith R, Alexander J, Barlow P, Botto M, Cassavant T, Cook H . New approaches to the treatment of dense deposit disease. J Am Soc Nephrol. 2007; 18(9):2447-56. PMC: 4853920. DOI: 10.1681/ASN.2007030356. View

19.

Schwertz R, Rother U, Anders D, Gretz N, Scharer K, Kirschfink M . Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. Pediatr Allergy Immunol. 2001; 12(3):166-72. DOI: 10.1034/j.1399-3038.2001.012003166.x. View

20.

Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sanchez-Corral P . The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol. 2004; 41(4):355-67. DOI: 10.1016/j.molimm.2004.02.005. View